GRACEcast Radiation Oncology Audio podcast

Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?

0:00
7:28
Retroceder 15 segundos
Avanzar 15 segundos

The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.

Otros episodios de "GRACEcast Radiation Oncology Audio"